JP7729000B2 - ６－アルコキシピラゾロピリミジン化合物及びその医薬用途 - Google Patents

６－アルコキシピラゾロピリミジン化合物及びその医薬用途

Info

Publication number
JP7729000B2
JP7729000B2 JP2025502778A JP2025502778A JP7729000B2 JP 7729000 B2 JP7729000 B2 JP 7729000B2 JP 2025502778 A JP2025502778 A JP 2025502778A JP 2025502778 A JP2025502778 A JP 2025502778A JP 7729000 B2 JP7729000 B2 JP 7729000B2
Authority
JP
Japan
Prior art keywords
disease
compound
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025502778A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024177126A5 (https=
JPWO2024177126A1 (https=
Inventor
雄介 大場
馨 足達
健太朗 櫻井
達也 西丸
洋介 生越
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of JPWO2024177126A1 publication Critical patent/JPWO2024177126A1/ja
Publication of JPWO2024177126A5 publication Critical patent/JPWO2024177126A5/ja
Priority to JP2025134721A priority Critical patent/JP2025169332A/ja
Application granted granted Critical
Publication of JP7729000B2 publication Critical patent/JP7729000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2025502778A 2023-02-24 2024-02-22 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途 Active JP7729000B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025134721A JP2025169332A (ja) 2023-02-24 2025-08-13 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023027437 2023-02-24
JP2023027437 2023-02-24
PCT/JP2024/006429 WO2024177126A1 (ja) 2023-02-24 2024-02-22 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025134721A Division JP2025169332A (ja) 2023-02-24 2025-08-13 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JPWO2024177126A1 JPWO2024177126A1 (https=) 2024-08-29
JPWO2024177126A5 JPWO2024177126A5 (https=) 2025-07-18
JP7729000B2 true JP7729000B2 (ja) 2025-08-25

Family

ID=92501358

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2025502778A Active JP7729000B2 (ja) 2023-02-24 2024-02-22 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途
JP2025134721A Pending JP2025169332A (ja) 2023-02-24 2025-08-13 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025134721A Pending JP2025169332A (ja) 2023-02-24 2025-08-13 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途

Country Status (4)

Country Link
EP (1) EP4671246A1 (https=)
JP (2) JP7729000B2 (https=)
CN (1) CN120731207A (https=)
WO (1) WO2024177126A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140708A1 (zh) * 2023-12-31 2025-07-03 杭州百新生物医药科技有限公司 吡唑并嘧啶类化合物及其医药用途
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534989A (ja) 2013-10-30 2016-11-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピラゾロピリミドンまたはピロロトリアゾン誘導体、その製造方法、およびそれらの医薬適用
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2020150115A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2020150114A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators, for use in the treatment of cancer
WO2021132577A1 (ja) 2019-12-27 2021-07-01 日本たばこ産業株式会社 アシルスルファミド化合物及びその医薬用途
WO2022212326A1 (en) 2021-03-29 2022-10-06 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022216680A1 (en) 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3229401A1 (en) * 2021-08-31 2023-03-09 Japan Tobacco Inc. 6-aminopyrazolopyrimidine compounds and medical use thereof
US20250114361A1 (en) * 2022-08-29 2025-04-10 Japan Tobacco Inc. Pyrazolopyrimidine compound and pharmaceutical use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534989A (ja) 2013-10-30 2016-11-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピラゾロピリミドンまたはピロロトリアゾン誘導体、その製造方法、およびそれらの医薬適用
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2020150115A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2020150114A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators, for use in the treatment of cancer
WO2021132577A1 (ja) 2019-12-27 2021-07-01 日本たばこ産業株式会社 アシルスルファミド化合物及びその医薬用途
WO2022212326A1 (en) 2021-03-29 2022-10-06 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022216680A1 (en) 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors

Also Published As

Publication number Publication date
EP4671246A1 (en) 2025-12-31
WO2024177126A1 (ja) 2024-08-29
JP2025169332A (ja) 2025-11-12
JPWO2024177126A1 (https=) 2024-08-29
CN120731207A (zh) 2025-09-30

Similar Documents

Publication Publication Date Title
JP7483810B2 (ja) ６－アミノピラゾロピリミジン化合物及びその医薬用途
JP7585409B2 (ja) ピラゾロピリミジン化合物及びその医薬用途
JP7729000B2 (ja) ６－アルコキシピラゾロピリミジン化合物及びその医薬用途
JP7737490B2 (ja) 置換ピラゾロピリミジン化合物及びその医薬用途
KR102588426B1 (ko) 치환 디히드로피롤로피라졸 유도체
JP2013507364A (ja) 新規なｔｒｐａ１アンタゴニスト
EP3831821A1 (en) Compound for treating nervous system diseases and use thereof
TW202000650A (zh) ４-甲基二氫嘧啶酮化合物及其醫藥用途
EP2832726B1 (en) (2-heteroarylamino)succinic acid derivative
CN109963836B (zh) 氘原子取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
HK40128856A (en) Pyrazolopyrimidine compound and pharmaceutical use thereof
CN117881682A (zh) 6-氨基吡唑并嘧啶化合物及其医药用途
HK40112889A (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
US20250333393A1 (en) Heterocyclic compound as tyk2 inhibitor, and synthesis and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250516

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250813

R150 Certificate of patent or registration of utility model

Ref document number: 7729000

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350